IN THE CLAIMS

This listing of claims replaces all prior versions, and listings, in this application.

1. (currently amended) A compound of formula (I), their analogs, their derivatives, their tautomers, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, and their pharmaceutically acceptable compositions, wherein G represents ~~substituted or unsubstituted, single or fused groups selcted from aryl group, heteroaryl or heterocyclic groups containing one or more heteroatom selected from O, S, N; preferably, G represents the groups~~ one of A, B, C, D, E, or [[&]] F as described below:



(I)

G =



A



B



C



D



E

F

R_1 represents hydrogen, substituted or unsubstituted groups selected the group consisting of from alkyl, aralkyl, acyl, alkylsulfonyl, and arylsulfonyl groups; R_2 represents alkyl, aralkyl, alkoxy or -NHR where R represents hydrogen or a lower alkyl group ~~groups~~ which may be suitably substituted; X_1, X_2, X_3, and X_4 may be same or different and represent hydrogen, cyano, nitro, halo, carboxyl, formyl, hydrazino, azido, amino, thio, hydroxy, or a substituted or unsubstituted group ~~groups~~ selected from the group consisting of alkyl which may be linear or branched, alkenyl, cycloalkyl, alkoxy, cycloalkoxy, cycloalkoxyalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, thioalkyl, carboxyalkyl, haloalkyl, aminoalkyl, cyanoalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkoxycarbonylalkyl, acyl, acyloxy, acyloxyalkyl, aralkyl, aryloxy, aralkoxy, aryloxyalkyl, aralkoxyalkyl, aralkenyl, acylamino, alkylamino, dialkylamino, aralkylamino,

alkoxyamino, hydroxylamino, alkoxycarbonyl, and aralkoxycarbonyl groups; ~~two adjacent groups may form a methylenedioxy or a ethylenedioxy group;~~ when G represents heterocycle "D", then ~~atleast~~ at least one of ~~the groups defined by~~ X_1, X_2, X_3, and X_4 is not hydrogen; R_3 represents a ~~is selected from~~ substituted or unsubstituted alkyl, or a substituted or unsubstituted, single or fused group ~~groups~~ selected from the group consisting of aryl, aralkenyl, heteroaryl, and [[or]] heterocyclic groups; R_4 and R_5 represent ~~is selected from~~ hydrogen atom, halogen atom, carboxy, or a substituted or unsubstituted group ~~groups~~ selected from the group consisting of linear or branched alkyl, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, and phenyl groups; Y represents O or S; and W represents O or S. [[;]]

2. (currently amended) The [[A]] compound as claimed in ~~according to~~ claim 1, wherein the substituents on R_3 and R_4 represent a ~~are selected from~~ cyano, nitro, halo, carboxyl, hydrazino, azido, formyl, amino, thio, hydroxy, ONO_2, alkyl-ONO_2 or substituted or unsubstituted group ~~groups~~ selected from the group consisting of alkyl which may be linear or branched, perhaloalkyl, alkoxy, hydrazinoalkyl, alkylhydrazido, acyl, acyloxy, oxo, carboxyalkyl, haloalkyl, aminoalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, thioalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylsulfoximinyl, aryl, aralkyl, aryloxy, aralkoxy, aryloxyalkyl, aralkoxyalkyl, aryloxycarbonyl, alkoxycarbonyl, aralkoxycarbonyl, alkoxycarbonylalkyl, amidino, carboxamidoalkyl, acylamino, cyanoamidino, cyanoalkyl, N-aminocarbonylalkyl, N-arylaminocarbonyl, carboxyalkylaminocarboxy, N-alkylamino, N,N-dialkylamino, N-arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylamino, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, N-arylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-alkyl-N-arylaminoalkyl, arylthio, aralkylthio, N-alkylaminosulfonyl, N-arylaminosulfonyl, arylsulfonyl, N,N-dialkylaminosulfonyl, N-alkyl-N-arylaminosulfonyl, alkoxycarbonyl, aminocarbonyl, cycloalkyl, heterocyclic, heterocyclicalkyl, heteroaryl, heteroaralkyl, heteroaralkoxy, and sulfamyl groups~~; two adjacent groups may form a methylenedioxy or a ethylenedioxy group~~.

3. (currently amended) The [[A]] compound as claimed in claim 1, wherein the ~~where suitable~~ substituents on X_1, X_2, X_3, and X_4 represent a ~~are selected from~~ cyano, nitro, halo, carboxyl, hydrazino, azido, formyl, amino, thio, hydroxy or substituted or unsubstituted group ~~groups~~ selected from the group consisting of alkyl which may be linear or branched, alkoxy, alkoxycarbonyl, acyl, acylamino, acyloxy,hydrazinoalkyl, alkylhydrazido, carboxyalkyl, haloalkyl, aminoalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, thioalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, aryl, aralkyl, aryloxy, aralkoxy, aryloxyalkyl, aralkoxyalkyl, alkoxycarbonyl, and amidino groups.

4. (currently amended) The [[A]] compound as claimed in ~~according to~~ claim 1, wherein the pharmaceutically acceptable salts are salts of tartaric acid, mandelic acid, fumaric acid, malic acid, lactic acid, maleic acid, salicylic acid, citric acid, ascorbic acid, benzene sulfonic acid, p-toluene sulfonic acid, hydroxynaphthoic acid, methane sulfonic acid, acetic acid, benzoic acid, succinic acid, palmitic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, or [[&]] nitric acid.

5. (currently amended) A pharmaceutical composition comprising one or more compounds as claimed in claim ~~Claim~~ 1 or a pharmaceutically-acceptable salt thereof and a pharmaceutically-acceptable carrier, diluent, excipient, ~~excipients~~ or solvate.

6. (currently amended) The [[A]] pharmaceutical composition as claimed in ~~according to~~ claim 1, in the form of a tablet, capsule, powder, granule, syrup, solution, or suspension.

7. (currently amended) A pharmaceutical composition which comprises[[,]] a pharmaceutically-acceptable salt as claimed in ~~compound according to~~ claim 4~~, as an active ingredient~~ and a pharmaceutically-acceptable carrier, diluent, excipient, ~~excipients~~ or solvate.

8. (currently amended) The [[A]] pharmaceutical composition as claimed in ~~which comprises, a compound according to~~ claim 7 [[4]], in the form of a tablet, capsule, powder, granule, syrup, solution, or suspension.

9. (currently amended) A method of treating inflammation or an inflammation-associated disorder in a subject, said method comprising treating the subject having or susceptible to such disorder with a therapeutically-effective amount of a compound as claimed in [[of]] claim 1 or a pharmaceutically acceptable salt thereof.

10. (currently amended) The method as claimed in claim 9, wherein the compound is administered orally, nasally, parenterally, topically, transdermally, or rectally.

11. (currently amended) A method of treating inflammation or an inflammation-associated disorder in a subject, said method comprising treating the subject having or susceptible to such disorder with a therapeutically-effective amount of a pharmaceutically-acceptable salt as claimed in ~~compound of~~ claim 4.

12. (currently amended) The method as claimed in claim 11, wherein the pharmaceutically-acceptable salt ~~compound~~ is administered orally, nasally, parenterally, topically, transdermally, or rectally.

13. (currently amended) The [[A]] compound as claimed in ~~according to~~ claim 1 which is selected from the group consisting of:
5-(4-Fluorophenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(4-Chlorophenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(4-Methylphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(4-Methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;
1-(4-methylsulfoximinylphenyl)-5-(4-*n*-propoxyphenyl)- 3-trifluoromethyl-1H-pyrazole;
5-(4-Ethoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(4-Hydroxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;

5-(3-Chloro-4-fluorophenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(3,4-Difluorophenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(4-Fluoro-3-methylphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(4-Methoxy-3-methylphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(3-Chloro-4-methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(3-Bromo-4-methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(3-Fluoro-4-methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(3-Methoxy-4-methylphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;
1-(2-Fluoro-4-methylsulfoximinylphenyl)-5-(4-Methoxyphenyl)-3-trifluoromethyl-1H-pyrazole;
1-(3-Fluoro-4-methylsulfoximinylphenyl)-5-(4-Methoxyphenyl)-3-trifluoromethyl-1H-pyrazole;
1-(4-Methylsulfoximinylphenyl)-5-phenyl-3-trifluoromethyl-1H-pyrazole;
1-(4-Methylsulfoximinylphenyl)-5-(1-naphthyl)-3-trifluoromethyl-1H-pyrazole;
5-(4-Methoxyphenyl)- 3-methyl-1-(4-methylsulfoximinylphenyl)-1H-pyrazole;
1-(4-Methylsulfoximinylphenyl)-5-(4-nitrophenyl)-3-trifluoromethyl-1H-pyrazole;
5-(3-Methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(3,5-Difluoro-4-Methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(3-Hydroxy-4-methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;
5-(4-Methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-1H-pyrazole-3-carboxylicacid;
3-(Hydroxymethyl)-5-(4-Methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-1H-pyrazole;

5-(4-Methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-1H-pyrazol-3-ylmethylhydrogen sulphate;

5-{4-(2-Hydroxy-ethoxy)phenyl}-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;

1-(4-Methylsulfoximinylphenyl)-5-(4-pyridyl)-3-trifluoromethyl-1H-pyrazole;

1-(4-Methylsulfoximinylphenyl)-5-(3-pyridyl)-3-trifluoromethyl-1H-pyrazole;

1-(4-Methylsulfoximinylphenyl)-5-(2-pyridyl)-3-trifluoromethyl-1H-pyrazole;

5-(4-Isopropoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;

1-(4-Methylsulfoximinylphenyl)-5-(2-thiophenyl)- 3-trifluoromethyl-1H-pyrazole;

5-(4-Methylsulfoxyminylphenyl)-1-phenyl -3- trifluoromethyl- 1H- pyrazole; [[.]]

1-(4-Methoxyphenyl)-5-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole;

5-Ethyl-4-(4-methylsulfoximinylphenyl)-3-phenyl-isoxazole;

5-Methoxymethyl-4-(4-methylsulfoximinylphenyl)-3-phenyl-isoxazole;

3-(4-Fluorophenyl)-5-methyl-4-(4-methylsulfoximinylphenyl)-isoxazole;

3-(4-Chlorophenyl)-5-methyl-4-(4-methylsulfoximinylphenyl)-isoxazole;

3-Ethyl-4-(4-methylsulfoximinylphenyl)-5-phenyl-isoxazole;

5-Chloro-4-(4-methylsulfoximinylphenyl)-3-phenyl-isoxazole;

5-Methyl-4-(4-methylsulfoximinylphenyl)-3-phenyl-isoxazole;

3-(4-Methoxyphenyl)-5-methyl-4-(4-methylsulfoximinylphenyl)-isoxazole;

3-(3,4-Dichlorophenyl)-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one;

3-(4-Chlorophenyl)-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one;

3-Phenyl-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one;

3-(3,4-Difluorophenyl)-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one;

3-(3,4-Dimethoxyphenyl)-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one;

3-(4-Methoxyphenyl)-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one;

3-(4-Methylphenyl)-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one;

5-Chloro-3-(4-methylsulfoximinylphenyl)-6'-methyl-[2,3']bipyridinyl;

5-Chloro-3-(4-methylsulfoximinylphenyl)-[2,3']bipyridinyl;

3-(3-Fluorophenyl)-4-(4-methylsulfoximinylphenyl)-3H-thiazol-2-one;

3-(3,4-Dichlorophenyl)-4-(4-methylsulfoximinylphenyl)-3H-oxazol-2-one;

3-(3,4-Dichlorophenyl)-4-(4-methylsulfoximinylphenyl)-3H-thiazol-2-one;
3-(2-Fluorophenyl)-4-(4-methylsulfoximinylphenyl)-3H-oxazol-2-one;
3-(4-Bromophenyl)-4-(4-methylsulfoximinylphenyl)-3H-oxazol-2-one;
4-(4-Methylsulfoximinylphenyl)-3-phenyl-3H-oxazol-2-one;
3-(3,4-Dichlorophenyl)-4-[4-(N-chloroacetyl) methylsulfoximinyl-phenyl]-3H-oxazol-2-one;
3-(3,4-Dichlorophenyl)-4-[4-(N-acetyl) methylsulfoximinyl-phenyl]-3H-oxazol-2-one;
3-(3,4-Dichlorophenyl)-4-[4-(N-methylsulfonyl)methylsulfoximinyl-phenyl]-3H-oxazol-2-one;
3-(3,4-Dichlorophenyl)-4-[4-{N-(4-methylphenyl)sulfonyl}-methylsulfoximinyl-phenyl]-3H-oxazol-2-one; and
pharmaceutically-acceptable salts thereof.

14. (currently amended) The [[A]] compound as claimed in ~~according to~~ claim 13, wherein the pharmaceutically acceptable salts are salts of tartaric acid, mandelic acid, fumaric acid, malic acid, lactic acid, maleic acid, salicylic acid, citric acid, ascorbic acid, benzene sulfonic acid, p-toluene sulfonic acid, hydroxynaphthoic acid, methane sulfonic acid, acetic acid, benzoic acid, succinic acid, palmitic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, or [[&]] nitric acid.

15. (currently amended) A pharmaceutical composition, which comprises a compound or pharmaceutically-acceptable salt thereof as claimed ~~defined~~ in claim 13 ~~claims 13 & 14~~, and a pharmaceutically acceptable carrier, diluent, excipient, ~~diluents or excipients~~ or solvate.

16. (currently amended) The [[A]] pharmaceutical composition as claimed in claim 15, in the form of a tablet, capsule, powder, granules, syrup, solution, or suspension.

17. (currently amended) A method of treating inflammation or an inflammation-associated disorder in a subject, said method comprising treating the subject having or

susceptible to such disorder with a therapeutically-effective amount of a compound ~~of claims 13-16~~ or [[a]] pharmaceutically acceptable salt thereof as claimed in claim 13.

Claim 18 (canceled)

19. (currently amended) A process for preparing a compound ~~the preparation of compounds~~ of formula (I),



(I)

wherein ~~Where~~ G represents ~~substituted or unsubstituted, single or fused groups selcted from aryl group, heteroaryl or heterocyclic groups containing one or more heteroatom selected from O, S, N~~; one of A, B, C, D, E, or F as described below:

G =



A



B



C



D



E



F

R_1 represents hydrogen, substituted or unsubstituted groups selected from the group consisting of alkyl, aralkyl, acyl, alkylsulfonyl, and arylsulfonyl groups; R_2 represents alkyl, aralkyl, or -NHR or -OR where R represents hydrogen or a lower alkyl group ~~groups~~ which may be suitably substituted; X_1, X_2, X_3, and X_4 may be same or different and represent hydrogen, cyano, nitro, halo, carboxyl, formyl, hydrazino, azido, amino,

thio, hydroxy, or a substituted or unsubstituted group ~~groups~~ selected from the group consisting of alkyl which may be linear or branched, alkenyl, oximealkyl, alkoxy, haloalkoxy, hydroxyalkyl, alkoxyalkyl, thioalkyl, carboxyalkyl, haloalkyl, aminoalkyl, cyanoalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkoxycarbonylalkyl, acyl, acyloxy, acyloxyalkyl, aralkyl, aryloxy, aralkoxy, aryloxyalkyl, aralkoxyalkyl, aralkenyl, acylamino, alkylamino, dialkylamino, aralkylamino, alkoxyamino, hydroxylamino, alkoxycarbonyl, and aralkoxycarbonyl groups; ~~two adjacent groups may form a methylenedioxy or a ethylenedioxy group;~~ when G represents heterocycle "D", then at least one of X_1, X_2, X_3, and X_4 is not hydrogen; R_3 represents a ~~is selected from~~ substituted or unsubstituted alkyl, or a substituted or unsubstituted, single or fused group ~~groups~~ selected from the group consisting of aryl, aralkenyl, heteroaryl, and [[or]] heterocyclic groups; R_4 and R_5 represent ~~is selected from~~ hydrogen atom, halogen atom, carboxy, or a substituted or unsubstituted group ~~groups~~ selected from the group consisting of linear or branched alkyl, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, and phenyl groups; Y represents O or S; and W represents O or S;

said process comprising: (a) oxidizing a compound of formula (P) to produce ~~get~~ a compound of formula (Q) and (b) iminating the compound of formula (Q) ~~which is iminated with suitable reagents~~ to produce a ~~get~~ compound of formula (I) ~~which may~~



(P) **(Q)** **(I)**

~~further be converted to their pharmaceutically acceptable salts, if desired~~.

20. (currently amended) The process as claimed in claim 19 further comprising converting the compound of formula (I) to its pharmaceutically-acceptable salt~~, where the groups representing G are preferably selected from A, B, C, D, E & F as described below, and all other symbols are as defined earlier~~.

G = 

A



B



C



D



E



F

21. (currently amended) A process for preparing a compound of general formula (P) as defined in claim 19 ~~claims 19 & 20~~, said process comprising ~~which comprises~~:

i. reacting a haloketone of formula (II) with a compound of formula (III) to obtain a mercapto compound of formula (P),



(II) (III) (P)

where G represents



A

and all other symbols are as defined earlier; [[.]]

ii. converting an [[the]] oxime of formula (VII) to a mercapto compound of formula (P),



(VII) (P)

where G represents



B

and all other symbols are as defined earlier;

iii. reacting a [[the]] hydrazine of formula (XI) with a 1,3-diketone of formula (XII) to form a [[the]] mercapto compound of formula (P),



(XI) (XII) (P)

where G represents



C

and all other symbols are as defined earlier; [[.]]

iv. reacting a compound of formula (XVII) with a compound of formula (XVIII) to form a ~~get~~ mercapto compound of formula (P),



(XVII) (XVIII) (P)

where G represents



D

and all other symbols are as defined earlier;

v. reacting a compound of formula (XXI) with a compound of formula (XXII) to form a ~~get~~ mercapto compound of formula (P),



(XXI) **(XXII)** **(P)**

where G represents



F

and all other symbols are as defined earlier.